Ironwood Pharma 
IRWD stock dropped ~89% in the past year due to disappointing Phase 3 Apraglutide trial results, FDA requiring an additional trial, weak Q1 2025 earnings (-$0.14 EPS vs. -$0.04 expected), high debt ($599.48M), and analyst downgrades. So why would I be interested in swing trading this company? The chart. The price has entered my "crash" simple moving average zone, which often results in a reversal - even if temporary. Also, Linzess (GI drug) revenue is steady, and I thoroughly believe that alone pushes the fair value near $0.95, if not higher. Thus, at $0.61, IRWD is in a personal buy zone with the potential for additional declines before future rise.
Target:
IRWD stock dropped ~89% in the past year due to disappointing Phase 3 Apraglutide trial results, FDA requiring an additional trial, weak Q1 2025 earnings (-$0.14 EPS vs. -$0.04 expected), high debt ($599.48M), and analyst downgrades. So why would I be interested in swing trading this company? The chart. The price has entered my "crash" simple moving average zone, which often results in a reversal - even if temporary. Also, Linzess (GI drug) revenue is steady, and I thoroughly believe that alone pushes the fair value near $0.95, if not higher. Thus, at $0.61, IRWD is in a personal buy zone with the potential for additional declines before future rise.Target:
- $0.95 (+55.7%)
Trade active
Cashed out half the position at $0.80 and set stop for entry. Total realized gain, thus far, +31.1%.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.